Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Tappenden

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Pharmacoeconomics|October 19, 2015
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalMunira Essat, Paul Tappenden, Shijie Ren, et al.
Frontiers in Neurology|April 8, 2021
The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDPRichard K Burt, Paul Tappenden, Roumen Balabanov, et al.
Health Technology Assessment (Winchester, England)|March 2, 2019
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic modelPaul Tappenden, Christopher Carroll, Jean Hamilton, et al.
BMJ (Clinical Research Ed.)|June 5, 2010
Continuing the multiple sclerosis risk sharing scheme is unjustifiedChristopher McCabe, Jim Chilcott, Karl Claxton, et al.
Pharmacoeconomics|September 25, 2018
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Emma Simpson, Jean Hamilton, et al.
International Journal of Technology Assessment in Health Care|October 15, 2010
Estimating the direct costs of bowel cancer services provided by the National Health Service in EnglandMatthew W Bending, Paul Trueman, Karin V Lowson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare populationPaul Tappenden, Christopher McCabe, Jim Chilcott, et al.
Pediatric Pulmonology|February 2, 2016
A systematic review of fractional exhaled nitric oxide in the routine management of childhood asthmaTim Gomersal, Sue Harnan, Munira Essat, et al.
The European Respiratory Journal|February 6, 2016
Fractional exhaled nitric oxide for the management of asthma in adults: a systematic reviewMunira Essat, Sue Harnan, Tim Gomersall, et al.
BMJ (Clinical Research Ed.)|March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosisJim Chilcott, Chris McCabe, Paul Tappenden, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Pharmacoeconomics|October 19, 2015
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalMunira Essat, Paul Tappenden, Shijie Ren, et al.
Frontiers in Neurology|April 8, 2021
The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDPRichard K Burt, Paul Tappenden, Roumen Balabanov, et al.
Health Technology Assessment (Winchester, England)|March 2, 2019
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic modelPaul Tappenden, Christopher Carroll, Jean Hamilton, et al.
BMJ (Clinical Research Ed.)|June 5, 2010
Continuing the multiple sclerosis risk sharing scheme is unjustifiedChristopher McCabe, Jim Chilcott, Karl Claxton, et al.
Pharmacoeconomics|September 25, 2018
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Emma Simpson, Jean Hamilton, et al.
International Journal of Technology Assessment in Health Care|October 15, 2010
Estimating the direct costs of bowel cancer services provided by the National Health Service in EnglandMatthew W Bending, Paul Trueman, Karin V Lowson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare populationPaul Tappenden, Christopher McCabe, Jim Chilcott, et al.
Pediatric Pulmonology|February 2, 2016
A systematic review of fractional exhaled nitric oxide in the routine management of childhood asthmaTim Gomersal, Sue Harnan, Munira Essat, et al.
The European Respiratory Journal|February 6, 2016
Fractional exhaled nitric oxide for the management of asthma in adults: a systematic reviewMunira Essat, Sue Harnan, Tim Gomersall, et al.
BMJ (Clinical Research Ed.)|March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosisJim Chilcott, Chris McCabe, Paul Tappenden, et al.
Pageof 9